• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

首个酮内酯类抗菌药物泰利霉素的微生物学特性

Microbiological profile of telithromycin, the first ketolide antimicrobial.

作者信息

Felmingham D

机构信息

GR Micro Ltd, London, UK.

出版信息

Clin Microbiol Infect. 2001;7 Suppl 3:2-10.

PMID:11523558
Abstract

Telithromycin, the first of the ketolide antimicrobials, has been specifically designed to provide potent activity against common and atypical/intracellular or cell-associated respiratory pathogens, including those that are resistant to beta-lactams and/or macrolide-lincosamide-streptograminB (MLS(B)) antimicrobials. Against gram-positive cocci, telithromycin possesses more potent activity in vitro and in vivo than the macrolides clarithromycin and azithromycin. It retains its activity against erm-(MLS(B)) or mef-mediated macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes and against Staphylococcus aureus resistant to macrolides through inducible MLS(B) mechanisms. Telithromycin also possesses high activity against the Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis, regardless of beta-lactamase production. In vitro, it shows similar activity to azithromycin against H. influenzae, while in vivo its activity against H. influenzae is higher than that of azithromycin. Telithromycin's spectrum of activity also extends to the atypical, intracellular and cell-associated pathogens Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae. In vitro, telithromycin does not induce MLS(B) resistance and it shows low potential to select for resistance or cross-resistance to other antimicrobials. These characteristics indicate that telithromycin will have an important clinical role in the empirical treatment of community-acquired respiratory tract infections.

摘要

泰利霉素是首个酮内酯类抗菌药物,其设计初衷是对常见的以及非典型/细胞内或与细胞相关的呼吸道病原体具有强大活性,包括那些对β-内酰胺类和/或大环内酯-林可酰胺-链阳菌素B(MLS(B))抗菌药物耐药的病原体。在体外和体内,泰利霉素对革兰氏阳性球菌的活性比克拉霉素和阿奇霉素等大环内酯类药物更强。它对erm-(MLS(B))或mef介导的大环内酯耐药肺炎链球菌和化脓性链球菌以及通过诱导型MLS(B)机制对大环内酯耐药的金黄色葡萄球菌仍保持活性。泰利霉素对革兰氏阴性病原体流感嗜血杆菌和卡他莫拉菌也具有高活性,无论其是否产生β-内酰胺酶。在体外,它对流感嗜血杆菌的活性与阿奇霉素相似,而在体内,它对流感嗜血杆菌的活性高于阿奇霉素。泰利霉素的活性谱还扩展到非典型、细胞内和与细胞相关的病原体嗜肺军团菌、肺炎支原体和肺炎衣原体。在体外,泰利霉素不会诱导MLS(B)耐药,并且它产生对其他抗菌药物耐药或交叉耐药的可能性较低。这些特性表明,泰利霉素在社区获得性呼吸道感染的经验性治疗中将发挥重要的临床作用。

相似文献

1
Microbiological profile of telithromycin, the first ketolide antimicrobial.首个酮内酯类抗菌药物泰利霉素的微生物学特性
Clin Microbiol Infect. 2001;7 Suppl 3:2-10.
2
In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.新型 6,11-桥联双环内酯类抗生素莫地霉素对包括耐大环内酯类阳性球菌在内的呼吸道病原体的体外抗菌活性。
Antimicrob Agents Chemother. 2011 Apr;55(4):1588-93. doi: 10.1128/AAC.01469-10. Epub 2011 Jan 10.
3
Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.泰利霉素对大环内酯类耐药和敏感的肺炎链球菌、卡他莫拉菌及流感嗜血杆菌的体外活性比较
J Antimicrob Chemother. 2004 May;53(5):793-6. doi: 10.1093/jac/dkh178. Epub 2004 Mar 31.
4
Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.社区获得性呼吸道病原体不断演变的耐药模式:PROTEKT全球监测研究的初步结果。酮内酯类药物泰利霉素的前瞻性耐药菌追踪与流行病学研究。
J Infect. 2002 Feb;44 Suppl A:3-10.
5
Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.与大环内酯类药物相比,泰利霉素对流感嗜血杆菌、卡他莫拉菌和链球菌的耐药性选择。
J Antimicrob Chemother. 2004 Aug;54(2):542-5. doi: 10.1093/jac/dkh339. Epub 2004 Jun 23.
6
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).拉丁美洲患者社区获得性呼吸道病原体的抗菌药物耐药性:PROTEKT监测研究(1999 - 2000年)结果
Braz J Infect Dis. 2003 Feb;7(1):44-61. doi: 10.1590/s1413-86702003000100006.
7
Comparative activity of telithromycin against typical community-acquired respiratory pathogens.泰利霉素对典型社区获得性呼吸道病原体的比较活性。
J Antimicrob Chemother. 2003 Sep;52(3):371-4. doi: 10.1093/jac/dkg359. Epub 2003 Jul 29.
8
Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.美国2000 - 2001年PROTEKT US研究中泰利霉素与β-内酰胺类抗菌药物对社区获得性细菌性呼吸道病原体的体外活性比较:研究结果
Clin Ther. 2004 Apr;26(4):522-30. doi: 10.1016/s0149-2918(04)90054-9.
9
Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.酮内酯类药物泰利霉素对主要呼吸道病原体分离株的临床和细菌学疗效:III期研究的汇总分析
Clin Microbiol Infect. 2004 Jan;10(1):27-36. doi: 10.1111/j.1469-0691.2004.00752.x.
10
Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.新型内酯酮内酯那氟沙星(WCK 4873)对来自全球监测计划的当代临床细菌的活性。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01230-17. Print 2017 Dec.

引用本文的文献

1
The Antibacterial and Antibiofilm Activity of Telithromycin Against spp. Isolated From Patients in China.替利福平对从中国患者中分离出的 菌的抗菌和抗生物膜活性。 (注:原文中“ spp.”部分信息缺失,翻译时保留原样)
Front Microbiol. 2021 Jan 14;11:616797. doi: 10.3389/fmicb.2020.616797. eCollection 2020.
2
Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.新型阳离子肽增强抗生素活性:SPR741的活性强度及活性谱
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00200-17. Print 2017 Aug.
3
Drug treatment of pneumococcal pneumonia in the elderly.
老年人肺炎球菌肺炎的药物治疗。
Drugs Aging. 2004;21(13):851-64. doi: 10.2165/00002512-200421130-00003.
4
Activity of telithromycin and comparators against bacterial pathogens isolated from 1,336 patients with clinically diagnosed acute sinusitis.替利霉素及对照药物对从1336例临床诊断为急性鼻窦炎患者中分离出的细菌病原体的活性。
Ann Clin Microbiol Antimicrob. 2004 Aug 2;3:15. doi: 10.1186/1476-0711-3-15.
5
High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.2000 - 2001年冬季德国耐红霉素肺炎链球菌分离株中ermB基因的高流行率及泰利霉素的体外活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3193-5. doi: 10.1128/AAC.48.8.3193-3195.2004.
6
New developments in antibacterial choice for lower respiratory tract infections in elderly patients.老年患者下呼吸道感染抗菌药物选择的新进展
Drugs Aging. 2004;21(3):167-86. doi: 10.2165/00002512-200421030-00003.
7
Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.化脓性链球菌临床分离株对泰利霉素和奎奴普丁-达福普汀的耐药性:SMART项目2001年数据。
Antimicrob Agents Chemother. 2003 Jul;47(7):2152-7. doi: 10.1128/AAC.47.7.2152-2157.2003.
8
Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.台湾地区对泰利霉素和氟喹诺酮耐药的肺炎链球菌,对大环内酯类和β-内酰胺类耐药率高:2001年SMART项目数据
Antimicrob Agents Chemother. 2003 Jul;47(7):2145-51. doi: 10.1128/AAC.47.7.2145-2151.2003.
9
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.2000年加拿大肺炎链球菌临床分离株中的抗菌药物耐药性。
Antimicrob Agents Chemother. 2002 May;46(5):1295-301. doi: 10.1128/AAC.46.5.1295-1301.2002.